One-year outcomes of ziv-aflibercept for macular edema in central retinal vein occlusion

Poster Details

First Author: J.Chhablani INDIA

Co Author(s):    M. Eldeeb   E. Chan   C. Dedhia   A. Mansour                    

Abstract Details


To report the 12-month efficacy and safety outcomes of intravitreal ziv-aflibercept in macular edema secondary to central retinal vein occlusion (CRVO).


Tertiary centre


Interventional case series documenting 12-month outcomes of intravitreal ziv-aflibercept in 6 patients with treatment-naive macular edema secondary to CRVO. All patients had comprehensive ophthalmic examination, spectral domain optical coherence tomography at baseline and all follow-up visits, and fluorescein angiography was performed. Retreatment decisions were based on recurrence or persistence of intraretinal or subretinal fluid, deterioration in visual acuity (VA), increase in central subfield thickness (CST) by ≥50 μm from the previous visit, or lowest recorded CST.


All participants were Middle-Eastern (2 males, 4 females), with a mean age of 53.5 years. From baseline to 12 months, the mean LogMAR VA improved from 0.86 (Snellen ≈ 20/145) to 0.33 (Snellen ≈ 20/40), and central macular thickness decreased from 519 μm to 255 μm. No eyes had uveitis, cataract progression, intraocular pressure (IOP) or elevations, or systemic adverse events.


Ziv-aflibercept achieves favorable intermediate-term functional and structural outcomes in macular edema secondary to CRVO. No safety concerns were raised. Low-cost ziv-aflibercept may thus be useful for CRVO in resource-poor countries. Further prospective studies in larger cohorts are needed further establish the efficacy and safety of this agent.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email:

Privacy policyHotel Terms and Conditions Cancellation policy